Statens Serum Institut

Statens Serum Institut (SSI) is a member of the Ministry of Health and Senior Affairs. Our main task is to ensure preparedness for infectious diseases, congenital disorders and biological threats. We monitor a large number of infectious diseases in Denmark and keep an eye on developments around the world via our international collaborations. Against this background, we advise healthcare professionals on prevention and treatment and advise decision-makers in situations that require special measures, for example in case of epidemics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIODURO LAUNCHES NEW ANTIBODY & CELL THERAPY DISCOVERY SERVICES

BioSpace | March 02, 2020

news image

BioDuro LLC, a leading global life sciences contract research and development organization, announced today that it has broadly launched new antibody- and cell-based therapy discovery services. The services have already been validated by early-access partners that have advanced several biologics-based therapies into the clinic. The Biologics Discovery team at BioDuro has more than 40 scientists and is led by a pharma- and biotech-experienced team with more than 100 years of combined biologics ex...

Read More

MEDICAL

MERCK ENTERS INTO SUPPLY AGREEMENT WITH U.S. GOVERNMENT TO MANUFACTURE AND INITIAL DISTRIBUTION OF INVESTIGATIONAL BIOLOGICAL THERAPEUTIC

Merck | December 28, 2020

news image

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today declared it has gone into a agreement with the United States Government to help the turn of events, assembling and introductory dispersion of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon endorsement or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the securing of OncoImmune, a privately held, clinical-stage biopharmaceuti...

Read More

GLOBAL CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET INSIGHTS 2019-2025

Galus | April 14, 2020

news image

Manufacturing process and technology used in CRISPR And CRISPR-Associated (Cas) Genes market, key developments and trends changing in the development Complete examination, including an evaluation of the parent market...

Read More

MEDICAL

ANITOA LAUNCHES MOLECULAR TEST (PCR) FOR MONKEYPOX

Anitoa | June 30, 2022

news image

Anitoa Systems, market leader in fast, portable molecular testing, today announced the availability of a CE-marked turn-key PCR solution for testing Monkeypox. This portable solution includes one of a family small foot-print real time PCR instruments called the Maverick qPCR, with an extraction-free multiplex PCR reagent that tests OPXV/MPXV gene-targets in the skin lesion sample from patients suspected of infection with Monkeypox. Anitoa's Monkeypox test is designed to be carried out on-sit...

Read More
news image

BIODURO LAUNCHES NEW ANTIBODY & CELL THERAPY DISCOVERY SERVICES

BioSpace | March 02, 2020

BioDuro LLC, a leading global life sciences contract research and development organization, announced today that it has broadly launched new antibody- and cell-based therapy discovery services. The services have already been validated by early-access partners that have advanced several biologics-based therapies into the clinic. The Biologics Discovery team at BioDuro has more than 40 scientists and is led by a pharma- and biotech-experienced team with more than 100 years of combined biologics ex...

Read More
news image

MEDICAL

MERCK ENTERS INTO SUPPLY AGREEMENT WITH U.S. GOVERNMENT TO MANUFACTURE AND INITIAL DISTRIBUTION OF INVESTIGATIONAL BIOLOGICAL THERAPEUTIC

Merck | December 28, 2020

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today declared it has gone into a agreement with the United States Government to help the turn of events, assembling and introductory dispersion of an investigational biological therapeutic (CD24Fc, to be named MK-7110) upon endorsement or Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). Merck acquired MK-7110 through the securing of OncoImmune, a privately held, clinical-stage biopharmaceuti...

Read More
news image

GLOBAL CRISPR AND CRISPR-ASSOCIATED (CAS) GENES MARKET INSIGHTS 2019-2025

Galus | April 14, 2020

Manufacturing process and technology used in CRISPR And CRISPR-Associated (Cas) Genes market, key developments and trends changing in the development Complete examination, including an evaluation of the parent market...

Read More
news image

MEDICAL

ANITOA LAUNCHES MOLECULAR TEST (PCR) FOR MONKEYPOX

Anitoa | June 30, 2022

Anitoa Systems, market leader in fast, portable molecular testing, today announced the availability of a CE-marked turn-key PCR solution for testing Monkeypox. This portable solution includes one of a family small foot-print real time PCR instruments called the Maverick qPCR, with an extraction-free multiplex PCR reagent that tests OPXV/MPXV gene-targets in the skin lesion sample from patients suspected of infection with Monkeypox. Anitoa's Monkeypox test is designed to be carried out on-sit...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us